SKYTROFA® is the first FDA‑approved once‑weekly treatment for pediatric GHD that offers:

  • Predictable release of somatropin from a prodrug over the course of one week1,2
  • Up to 86% fewer injections per year compared with daily therapies1,3
  • Higher mean annualized height velocity (AHV) at week 52 in a clinical trial1,2*

Treatment difference in least squares mean AHV of 0.9 cm/year (11.2 cm/year for SKYTROFA compared with 10.3 cm/year for a daily somatropin) with 95% CI: 0.2 to 1.5 cm/year.1,2

  • No refrigeration required for up to 6 months1

* In the phase 3 heiGHt trial comparing once-weekly SKYTROFA with a daily somatropin in 161 treatment-naïve children with GHD. The primary endpoint was mean AHV at week 52.1,2